Cargando…
Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia
BACKGROUND: Ataxia-telangiectasia (A-T) is a DNA repair disorder characterized by changes in several organs and systems. Advances in clinical protocols have resulted in increased survival of A-T patients, however disease progression is evident, mainly through metabolic and liver changes. OBJECTIVE:...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161655/ https://www.ncbi.nlm.nih.gov/pubmed/37147676 http://dx.doi.org/10.1186/s13023-023-02720-7 |
_version_ | 1785037538450210816 |
---|---|
author | Barreto, Talita Lemos Neves de Carvalho Filho, Roberto José Shigueoka, David Carlos Fonseca, Fernando Luiz Affonso Ferreira, Ariel Cordeiro Kochi, Cristiane Aranda, Carolina Sanchez Sarni, Roseli Oselka Saccardo |
author_facet | Barreto, Talita Lemos Neves de Carvalho Filho, Roberto José Shigueoka, David Carlos Fonseca, Fernando Luiz Affonso Ferreira, Ariel Cordeiro Kochi, Cristiane Aranda, Carolina Sanchez Sarni, Roseli Oselka Saccardo |
author_sort | Barreto, Talita Lemos Neves |
collection | PubMed |
description | BACKGROUND: Ataxia-telangiectasia (A-T) is a DNA repair disorder characterized by changes in several organs and systems. Advances in clinical protocols have resulted in increased survival of A-T patients, however disease progression is evident, mainly through metabolic and liver changes. OBJECTIVE: To identify the frequency of significant hepatic fibrosis in A-T patients and to verify the association with metabolic alterations and degree of ataxia. METHODS: This is a cross-sectional study that included 25 A-T patients aged 5 to 31 years. Anthropometric data, liver, inflammatory, lipid metabolism and glucose biomarkers (oral glucose tolerance test with insulin curve—OGTT) were collected. The Cooperative Ataxia Rating Scale was applied to assess the degree of ataxia. The following were calculated: Homeostasis Model Assessment—Insulin Resistance, Homeostasis Model Assessment—Adiponectin (HOMA-AD), Matsuda index, aspartate aminotransferase (AST): platelet ratio index, nonalcoholic fatty liver disease fibrosis score and BARD score. Liver ultrasonography and transient liver elastography by FibroScan(®) were performed. RESULTS: Significant hepatic fibrosis was observed in 5/25 (20%). Patients in the group with significant hepatic fibrosis were older (p < 0.001), had lower platelet count values (p = 0.027), serum albumin (p = 0.019), HDL-c (p = 0.013) and Matsuda index (p = 0.044); and high values of LDL-c (p = 0.049), AST (p = 0.001), alanine aminotransferase (p = 0.002), gamma-glutamyl transferase (p = 0.001), ferritin (p = 0.001), 120-min glycemia by OGTT (p = 0.049), HOMA-AD (p = 0.016) and degree of ataxia (p = 0.009). CONCLUSIONS: A non-invasive diagnosis of significant hepatic fibrosis was observed in 20% of A-T patients associated with changes in liver enzymes, ferritin, increased HOMA-AD, and the severity of ataxia in comparison with patients without hepatic fibrosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-023-02720-7. |
format | Online Article Text |
id | pubmed-10161655 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101616552023-05-06 Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia Barreto, Talita Lemos Neves de Carvalho Filho, Roberto José Shigueoka, David Carlos Fonseca, Fernando Luiz Affonso Ferreira, Ariel Cordeiro Kochi, Cristiane Aranda, Carolina Sanchez Sarni, Roseli Oselka Saccardo Orphanet J Rare Dis Research BACKGROUND: Ataxia-telangiectasia (A-T) is a DNA repair disorder characterized by changes in several organs and systems. Advances in clinical protocols have resulted in increased survival of A-T patients, however disease progression is evident, mainly through metabolic and liver changes. OBJECTIVE: To identify the frequency of significant hepatic fibrosis in A-T patients and to verify the association with metabolic alterations and degree of ataxia. METHODS: This is a cross-sectional study that included 25 A-T patients aged 5 to 31 years. Anthropometric data, liver, inflammatory, lipid metabolism and glucose biomarkers (oral glucose tolerance test with insulin curve—OGTT) were collected. The Cooperative Ataxia Rating Scale was applied to assess the degree of ataxia. The following were calculated: Homeostasis Model Assessment—Insulin Resistance, Homeostasis Model Assessment—Adiponectin (HOMA-AD), Matsuda index, aspartate aminotransferase (AST): platelet ratio index, nonalcoholic fatty liver disease fibrosis score and BARD score. Liver ultrasonography and transient liver elastography by FibroScan(®) were performed. RESULTS: Significant hepatic fibrosis was observed in 5/25 (20%). Patients in the group with significant hepatic fibrosis were older (p < 0.001), had lower platelet count values (p = 0.027), serum albumin (p = 0.019), HDL-c (p = 0.013) and Matsuda index (p = 0.044); and high values of LDL-c (p = 0.049), AST (p = 0.001), alanine aminotransferase (p = 0.002), gamma-glutamyl transferase (p = 0.001), ferritin (p = 0.001), 120-min glycemia by OGTT (p = 0.049), HOMA-AD (p = 0.016) and degree of ataxia (p = 0.009). CONCLUSIONS: A non-invasive diagnosis of significant hepatic fibrosis was observed in 20% of A-T patients associated with changes in liver enzymes, ferritin, increased HOMA-AD, and the severity of ataxia in comparison with patients without hepatic fibrosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-023-02720-7. BioMed Central 2023-05-05 /pmc/articles/PMC10161655/ /pubmed/37147676 http://dx.doi.org/10.1186/s13023-023-02720-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Barreto, Talita Lemos Neves de Carvalho Filho, Roberto José Shigueoka, David Carlos Fonseca, Fernando Luiz Affonso Ferreira, Ariel Cordeiro Kochi, Cristiane Aranda, Carolina Sanchez Sarni, Roseli Oselka Saccardo Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia |
title | Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia |
title_full | Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia |
title_fullStr | Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia |
title_full_unstemmed | Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia |
title_short | Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia |
title_sort | hepatic fibrosis: a manifestation of the liver disease evolution in patients with ataxia-telangiectasia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161655/ https://www.ncbi.nlm.nih.gov/pubmed/37147676 http://dx.doi.org/10.1186/s13023-023-02720-7 |
work_keys_str_mv | AT barretotalitalemosneves hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia AT decarvalhofilhorobertojose hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia AT shigueokadavidcarlos hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia AT fonsecafernandoluizaffonso hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia AT ferreiraarielcordeiro hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia AT kochicristiane hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia AT arandacarolinasanchez hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia AT sarniroselioselkasaccardo hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia |